Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 420 participants.

Also called NCT04491695

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 420 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04491695
Other papers using this trial's data
  • Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial JAMA neurology, 2024-06-01 DOI, PubMed 38648030, PMC11036313 PubMed links an erratum for this paper. Erratum: PMID 38949819 Not in the PMC Open Access subset.
  • Effects of tirofiban in preventing neurological deterioration in acute ischemic stroke with intracranial artery stenosis: A post hoc analysis of the TREND Trial European stroke journal, 2025-09 DOI, PubMed 39950764, PMC11829278 Not in the PMC Open Access subset.
  • Stroke etiology was associated with tirofiban efficacy in acute ischemic stroke without endovascular treatment: A pre-specified subgroup analysis of the TREND trial International journal of stroke : official journal of the International Stroke Society, 2025-10 DOI, PubMed 40012523

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04491695. Randomized; single masking; primary purpose treatment. Start 2020-09-12 (actual); primary completion 2022-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke
Acronym
TREND
Condition
Acute Stroke
Intervention (Drug)
Tirofiban Hydrochloride
Intervention (Drug)
Oral antiplatelet
Lead sponsor
Capital Medical University (class: other)

Record details

Record id
cardio:ct-nct04491695
Content hash
997e47c5a7d0029477bb85de6295948561cad3148a6cd389e241f6edf926c952